IVF Stock Forecast: INVO Fertility, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering INVO Fertility, Inc. hold a median 12-month price target of $20 — +1951.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 1 Aug 2026 — in the lower half.
IVF stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores INVO Fertility, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (13): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own INVO Fertility, Inc. — and when they’d sell — is the membership.
IVF stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IVF, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1951.3% from it.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IVF analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
INVO Fertility, Inc. (IVF) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- 0.2×
- Price / book
- 0.1×
- EV / EBITDA
- −0.2×
Cheaper than 74% of US stocks
Cheaper than 91% of US stocks
Cheaper than 90% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- 23.1%
- Earnings growth (YoY)
- —
- Gross margin
- 36.1%
- Operating margin
- −78.9%
- Net margin
- −158.7%
Higher than 75% of US stocks
Higher than 46% of US stocks
Higher than 15% of US stocks
Higher than 3% of US stocks
- Return on equity
- −102.2%
- Return on assets
- −13.8%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IVF vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IVF appears on the weeks it earns a place.
Frequently asked questions about IVF stock
What is the IVF stock price forecast for 2026-2027?
The 1 Wall Street analysts covering INVO Fertility, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IVF stock a buy right now?
Of the 1 analysts covering INVO Fertility, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks INVO Fertility, Inc. 47 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IVF?
As at 1 Aug 2026, INVO Fertility, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
Will IVF stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +1951.3% from the last close, and Ticker Nerd's factor model ranks INVO Fertility, Inc. 47 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IVF stock forecast for 2030?
No analyst covering INVO Fertility, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IVF are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.
How has IVF stock performed over the past year?
INVO Fertility, Inc. returned -98.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does INVO Fertility, Inc. do?
INVO Fertility, Inc. is a healthcare services company focused on the fertility market, providing assisted reproductive technology care through innovative clinic operations and medical devices.
About INVO Fertility, Inc.
INVO Fertility, Inc. is a healthcare services company focused on the fertility market, providing assisted reproductive technology care through innovative clinic operations and medical devices. It operates fertility clinics, including branded INVO Centers dedicated primarily to the intravaginal culture procedure enabled by its proprietary INVOcell device, as well as traditional in vitro fertilization clinics. The INVOcell is a medical device that facilitates fertilization and early embryo development in vivo within the woman's body, offering an alternative to conventional lab-based methods. The company also sells and distributes the INVOcell device to third-party fertility clinics. Its services encompass a range of reproductive options such as IVF, intravaginal culture, intrauterine insemination, fertility preservation, and advanced diagnostic testing. INVO Fertility, Inc. maintains a network of operational clinics in the United States and pursues acquisitions to expand its platform. Founded in 2007 and headquartered in Sarasota, Florida, it plays a role in making fertility treatments more accessible in the healthcare sector.
CEO Mr. Steven M. Shum · 40 employees · United States · https://www.invofertility.com